Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 06, 2018 13:00 ET | Source: Nohla Therapeutics

Nohla Therapeutics Receives FDA Fast Track Designation for Dilanubicel for Allogeneic Cord Blood Transplant Patients

SEATTLE, Aug. 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
June 15, 2018 11:30 ET | Source: Nohla Therapeutics

Nohla Announces Presentation of Dilanubicel (NLA101) Data at EHA Annual Meeting Showcasing Excellent Long-term Survival Outcomes

SEATTLE, June 15, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
June 06, 2018 13:00 ET | Source: Nohla Therapeutics

Nohla Receives EMA PRIME Designation for Dilanubicel (NLA101) to Treat Hematopoietic Stem Cell Transplant Patients

SEATTLE, June 06, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignancies and other critical diseases,...
May 17, 2018 13:00 ET | Source: Nohla Therapeutics

Nohla Announces EHA Abstract Acceptance on Dilanubicel (NLA101) Off-the-Shelf Cell Therapy Showing Excellent Long-term Survival Outcomes

SEATTLE, May 17, 2018 (GLOBE NEWSWIRE) -- Nohla Therapeutics, a leading developer of universal, off-the-shelf cell therapies for patients with hematologic malignances and other critical diseases,...